A PYMNTS Company

UK: Competition watchdog launches inquiry into Canadian pharma company

By  |  October 11, 2017

Concordia International a Canada-based pharmaceutical company, said Wednesday October 11, that its International segment and certain of its products are part of an investigation into new issues in the UK pharmaceutical sector by the UK Competition and Markets Authority (CMA).

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The company said the investigation is at an early, information-gathering stage and that the CMA has confirmed that, at this time, it has not reached any conclusions on whether competition law has been infringed.

    The company also said that the investigation includes matters that pre-date its ownership of the International segment. Concordia acquired the International segment as a result of its transaction to purchase Amdipharm Mercury Limited, which closed on October 21, 2015.

    Full Content: Street Insider

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.